Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Regen BioPharma (RGBPP) Shares Outstanding (Weighted Average) (2016 - 2025)

Regen BioPharma (RGBPP) has disclosed Shares Outstanding (Weighted Average) for 13 consecutive years, with $23.8 million as the latest value for Q2 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 497.63% to $23.8 million in Q2 2025 year-over-year; TTM through Jun 2025 was $23.8 million, a 497.63% increase, with the full-year FY2024 number at $4.1 million, up 16.21% from a year prior.
  • Shares Outstanding (Weighted Average) was $23.8 million for Q2 2025 at Regen BioPharma, up from $21.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $4.5 billion in Q4 2021 to a low of $1.7 million in Q1 2023.
  • A 5-year average of $739.1 million and a median of $4.0 million in 2024 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): plummeted 99.93% in 2022, then surged 497.63% in 2025.
  • Regen BioPharma's Shares Outstanding (Weighted Average) stood at $4.5 billion in 2021, then tumbled by 99.93% to $3.4 million in 2022, then rose by 7.01% to $3.6 million in 2023, then grew by 14.3% to $4.1 million in 2024, then skyrocketed by 477.88% to $23.8 million in 2025.
  • Per Business Quant, the three most recent readings for RGBPP's Shares Outstanding (Weighted Average) are $23.8 million (Q2 2025), $21.6 million (Q1 2025), and $4.1 million (Q4 2024).